OncoResponse Awarded $13 Million in Funding from CPRIT and Raises $14 Million in Added Funds from Investors to Advance Cancer Immunotherapy

OncoResponse announced it has been awarded a $13 million grant from the Cancer Prevention and Research Institute of Texas (CPRIT). The CPRIT award and investment will support the advancement of OR502, a best-in-class anti-LILRB2 antibody poised to move to investigational new drug and clinical studies.